New Jersey-based oncology company NovoCure Limited has been making strides in the treatment of solid tumor cancers with its revolutionary tumor treating fields (TTFields) devices. The devices are available in several regions across the globe, including the United States, Europe, the Middle East, Africa, Japan, and Greater China. Novocure Limited's portfolio of TTFields devices includes Optune, which is used to treat glioblastoma, and Optune Lua, designed for the treatment of malignant pleural mesothelioma. The company is also claiming significant progress in a range of clinical trials investigating TTFields treatment for brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited has been in existence for over twenty years, having been incorporated in 2000, and is headquartered in Saint Helier, Jersey.
NovoCure's ticker is NVCR
The company's shares trade on the NASDAQ stock exchange
They are based in Portsmouth, New Hampshire
There are 201-500 employees working at NovoCure
It is novocure.com
NovoCure is in the Healthcare sector
NovoCure is in the Medical Laboratories & Research industry
The following five companies are NovoCure's industry peers: